Myasthenia Gravis Disease Market Extends to CAGR of 7.5% Globally, Top Players Valeant Pharmaceuticals, Sun Pharmaceuticals, Novartis and Bristol-Myers Squibb Forecast upto 2023

Myasthenia gravis is a neuromuscular disorder that leads to the weakening of skeletal muscles, which are responsible for the movement of the body. This condition occurs due to the impairment of communication between muscles and nerve cells. This impairment causes difficulties in the contraction and relaxation of muscles which are crucial for carrying out daily activities, resulting in muscle weakness. It mostly affects the muscles that control the eyes and eyelids, facial expressions, chewing, and speaking. As per a study conducted by the Myasthenia Gravis Foundation of America, myasthenia gravis is the most common type of neuromuscular disorder. It is a rare condition with a prevalence of 14 to 20 cases per 100,000 people in the United States.

Numerous organizations are undertaking global initiatives and spreading awareness about this disease. Some of these are as follows: Myasthenia Gravis Foundation of America, Inc., American Autoimmune Related Diseases Association, Muscular Dystrophy Association, and others.

The prognosis of the patients of myasthenia gravis is usually good and the quality of treatment can subside the disease if treated at early stages. This condition can occur both in males and females and all ethnic groups. It usually affects women under 40 and the geriatric population from 50 to 70 years old. Younger patients are rarely diagnosed with the myasthenia gravis disease also known as thymus tumor (thymoma). According to the National Institute of Neurological Disorders and Stroke (NINDS) about 60,000 Americans suffer from neuromuscular disorders each year in the U.S.

Factors such as increasing cases of neuromuscular disorders, growing awareness regarding the treatment line, and increasing number of clinical facilities across the region are driving the market growth. However, the high cost of treatment and ignorance of signs and symptoms are constraining the growth of the market. The global market for the myasthenia gravis disease is expected to grow at a CAGR of approximately 7.5% during 2017 to 2023.

Get Exclusive Report Here - https://www.marketresearchfuture.com/sample_request/5843

Myasthenia Gravis Disease Market: Key Players

Valeant Pharmaceuticals International (U.S.), Sun Pharmaceuticals Industries Ltd. (India), Piramal Healthcare (India), Novartis Pharmaceuticals Corporation (Switzerland), Apotex Corporation (Canada), Teva Pharmaceutical Industries Ltd. (Israel), RPG Life Sciences (India), Cipla (India), F. Hoffmann Roche La Ltd. (Switzerland), Bristol-Myers Squibb Company (U.S.), Biogen Inc. (U.S.), and AbbVie Inc. (U.S.), GlaxoSmithKline plc (UK), Fresenius Kabi (Germany), and others.

Myasthenia Gravis Disease Market: Segmentation

The global myasthenia gravis disease market has been segmented on the basis of diagnosis, treatment, and end-user. On the basis of diagnosis, the global myasthenia gravis disease market can be segmented into imaging, blood tests, electrodiagnostic, edrophonium test, pulmonary function test, and others. The imaging segment is classified into X-ray, Computed Tomography (CT), Magnetic Resonance Imaging (MRI), and others.

On the basis of treatment, the global myasthenia gravis disease market can be segmented into medication, surgery, autologous Hematopoietic Stem Cell Transplantation (HSCT), plasmapheresis and intravenous immunoglobulin, and others. The medication segment is divided into acetylcholinesterase inhibitors, immunosuppressant drugs, steroids, and others. The acetylcholinesterase inhibitors are classified into atropine, neostigmine, pyridostigmine, and others. The immunosuppressant drugs are further divided into prednisone, azathioprine, mycophenolate mofetil, tacrolimus, and rituximab. The steroids are further divided into prednisone and others. The surgery is finally divided into thymectomy and others. On the basis of end-user, the global myasthenia gravis disease market is segmented into hospitals, clinics, academic research institutes, and others.

Myasthenia Gravis Disease Market : Regional Analysis

The global myasthenia gravis disease market consists of regions, namely, the Americas, Europe, Asia Pacific, and the Middle East and Africa. The Americas dominates the global myasthenia gravis disease market owing to the growing prevalence of muscular dystrophies such as congenital muscular dystrophies, distal muscular dystrophy, Becker muscular dystrophies, and others along with the extensive demand for diagnostic and treatment services. Moreover, major companies are launching FDA approved drugs thus increasing the commercial access to these drugs worldwide.

The European region is the second largest market for the global myasthenia gravis disease owing to the adoption of new therapies, skilled medical professionals, and availability of advanced treatment facilities. According to the National Institute of Neurological Disorders and Stroke (NINDS), an estimated 15 cases of myasthenia gravis occurs per 100,000 people in the United Kingdom every year.

The Asia Pacific market is the fastest growing therapeutic market owing to the large aging population in countries such as Japan and China coupled with the rising awareness about the long-term effects of muscular dystrophies. Moreover, the cumulative initiatives of the World Health Organization (WHO) in countries such as Japan, China, and India are likely to foster the strengthening of major Asian countries in the future. The Middle East and Africa is likely to exhibit steady growth in this market due to the demand for drugs in remote areas and increasing prevalence of neurological diseases.

Access Report Details @ https://www.marketresearchfuture.com/reports/myasthenia-gravis-disease-market-5843

TABLE OF CONTENT

Chapter 1. Report Prologue

Chapter 2. Market Introduction
2.1 Definition
2.2 Scope Of The Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations

Chapter 3. Research Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation

Chapter 4. Market Dynamics
4.1 Drivers
4.2 Restraints
4.3 Opportunities
4.4 Challenges
4.5 Macroeconomic Indicators
4.6 Technology Trends & Assessment

About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Statistical Report, Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Market Research Future
Office №528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune — 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com

This release was published on openPR.